Overview
Claims allege that long-term use of Depo-Provera (medroxyprogesterone) caused meningioma, a type of brain tumor. A 2024 BMJ study reported an increased risk (per the study). Federal cases are consolidated in MDL 3140, In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, before Judge M. Casey Rodgers in the Middle District of Florida (per JPML). In June 2026 a global settlement resolving the meningioma claims was reached; claims remain fileable under the settlement program as of August 2026 (per public reports and firm pages). No outcomes or amounts can be promised.
Status of the science / claims: A 2024 BMJ study reported an increased risk of meningioma (a type of brain tumor) with long-term Depo-Provera use (per the study).
Key people
Companies involved
Settlement amounts
Global settlement reached June 2026 (per public reports); per-claim amounts depend on the claim and the settlement program. Claims remain fileable (per firm pages, Aug 2026). No outcome can be promised.
Key dates
- June 1, 2026Global settlement reached resolving meningioma claims; claims remain fileable (per public reports)
- February 7, 2025JPML transfer/consolidation: MDL 3140, M.D. Fla., Judge M. Casey Rodgers (per JPML)
- January 1, 2024BMJ study reports increased meningioma risk with long-term Depo-Provera use (per the study)
Updates
- Updated Sep 1, 2026Federal cases consolidated in MDL 3140 (M.D. Fla., Judge M. Casey Rodgers, per JPML); global settlement June 2026 remains in effect.
- Updated Jun 15, 2026Seeded from research (Jun 2026): global settlement reached for meningioma claims; claims remain fileable (per public reports).
Notable filings
No notable filings recorded yet. Docket entries are added from public court records as they appear.
FAQ
What is the Depo-Provera lawsuit about?
Claimants allege that long-term use of Depo-Provera (medroxyprogesterone) caused meningioma, a type of brain tumor (per complaints). A 2024 BMJ study reported an increased risk (per the study).
Who is the defendant?
Pfizer, the maker of Depo-Provera (per complaints and public reports).
Was a settlement reached?
Yes — a global settlement resolving the meningioma claims was reached in June 2026 (per public reports).
Can I still file a claim?
Yes — claims remain fileable under the settlement program as of August 2026 (per public reports and firm pages). The program has its own deadlines; consult a licensed attorney.
How much will I receive?
Per-claim amounts depend on the claim and the settlement program (per public reports); no outcome or amount can be promised.
What is the status of the science?
A 2024 BMJ study reported an increased risk of meningioma associated with long-term Depo-Provera use (per the study); Pfizer has contested the association (per public reports). The litigation record is the place to track how the evidence is being weighed.
Think this matters to you?
This page is neutral reference material — not legal advice. If you were affected, the next step is a free case review with a licensed attorney working this matter.
Start free case review →